Idiopathic Pulmonary Fibrosis Market Size to Exceed USD 8,875.9 Mn by 2032

The Idiopathic Pulmonary Fibrosis Market, estimated at USD 4,950 Mn in 2025, is expected to exhibit a CAGR of 8.7% and reach USD 8,875.9 Mn by 2032.

The market growth is driven by increasing demand for innovative and effective drugs across diverse therapeutic areas. Advances in drug discovery, biopharmaceuticals, and digital technologies are improving treatment outcomes and operational efficiency. Supportive regulations, rising R&D investments, and a strong focus on patient-centric care are creating new opportunities for pharmaceutical companies.

The market players are focusing on research and development activities for the treatment of patients suffering from idiopathic pulmonary fibrosis, and this  is expected to drive global idiopathic pulmonary fibrosis market growth over the forecast period. For instance, in June 2025, Redx Pharma, a pharmaceutical company, announced that the first healthy volunteer had been dosed in a Phase I clinical evaluating RXC007, an investigational oral therapy for Idiopathic Pulmonary Fibrosis (IPF), and other fibrotic or scarring-related conditions.

Global Idiopathic Pulmonary Fibrosis Market– Impact of Coronavirus (COVID-19) Pandemic

The World Health Organization (WHO) designated the illness caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that first appeared in Wuhan, (province of Hubei, China) in the last months of 2025 as "coronavirus disease 2025," or COVID-19. This virus spreads quickly, and had a serious negative impact on the economies, social behaviors, and healthcare of every country in the world.

The COVID-19 affected the economy in three main ways: by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to the lockdown, several countries such as India, China, Brazil, and others faced problems regarding transportation of drugs from one place to another.

The COVID-19 had a positive impact on the global idiopathic pulmonary fibrosis market, as patients suffering from idiopathic pulmonary fibrosis where more likely to get affected by COVID -19, thus leading to increasing growth of the market during the pandemic. For instance, in April 2025, according to the report published by National Center for Biotechnology Information, approximately 44.9% of COVID-19 survivors had pulmonary fibrosis. Factors related to COVID-19 severity were significantly associated with PCPF (post-COVID-19 pulmonary fibrosis) development.

Global Idiopathic Pulmonary Fibrosis Market: Key Developments

In July 2025, Daewoong Pharmaceutical, a pharmaceutical company, announced that Daewoong Pharmaceutical's new medication named DWN12088 had been fast-tracked by the U.S. FDA. DWN12088 is a new treatment for idiopathic pulmonary fibrosis that is currently under development, and had been selected by the U.S. FDA for its rapid drug screening process (fast-track).

In July 2025, FibroGen, a biotechnology company, announced that FG-3019, the company's human monoclonal antibody against connective tissue growth factor (CTGF), had been granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of idiopathic pulmonary fibrosis (IPF).

Browse 58 Market Data Tables and 53 Figures spread through 339 Pages and in-depth TOC on “Global Idiopathic Pulmonary Fibrosis Market”- Forecast to 2032, By Drug (Pirfenidone, Nintedanib, and Others(Interferon gamma-1b and Others)), By Route of Administration (Oral and Parenteral), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies ), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

To know the latest trends and insights prevalent in this market, click the link below:

https://www.coherentmarketinsights.com/market-insight/idiopathic-pulmonary-fibrosis-treatment-market-2466

Key Takeaways of the Global Idiopathic Pulmonary Fibrosis Market:

• Global idiopathic pulmonary fibrosis market is expected to exhibit a CAGR of 8.7% during the forecast period. Increasing research and development activities by key market players is expected to drive the market growth over the forecast period. For instance, in August 2025, Blade Therapeutics, Inc., a biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had activated the company’s investigational new drug (ind) application to investigate cudetaxestat in IPF (Idiopathic Pulmonary Fibrosis). Cudetaxestat is a non-competitive autotaxin inhibitor for fibrotic diseases.
• Among region, North America is expected to be the most dominant region in the global idiopathic pulmonary fibrosis market, owing to increasing approvals from the U.S. FDA (Food and Drug Administration) for the treatment of idiopathic pulmonary fibrosis in this region by the key market players. For instance, in December 2025, Algernon Pharmaceuticals Inc., a clinical stage pharmaceutical company, announced that the U.S. Food and Drug Administration (U.S. FDA) had granted Orphan Drug Designation (ODD) to Ifenprodil for treatment of Idiopathic Pulmonary Fibrosis (IPF). Ifenprodil is an active ingredient in NP-120, an NMDA(N-methyl-D-aspartate) receptor antagonist and the Company’s lead clinical candidate that is being developed for the treatment of idiopathic pulmonary fibrosis and chronic cough.
• Major players operating in the global idiopathic pulmonary fibrosis market include Genentech, Inc., Boehringer Ingelheim International GmbH, Avalyn Pharma, Inc., AstraZeneca, Blade Therapeutics, Bristol-Myers Squibb Company, Cipla Inc., F. Hoffmann-La Roche, FibroGen, Inc., Galapagos NV, MediciNova, Inc., Merck & Co., Inc., Promedior, Inc., Prometic Life Sciences Inc., Daewoong Pharmaceutical (India) Pvt Ltd, Sandoz International GmbH (Novartis), and Algernon Pharmaceuticals Inc.